TScan Therapeutics, Inc. (TCRX) · 10+ Years of Financial statements

Income Statement	2019 Y	2020 Y	2021 Y	2022 Y	2023 Y
Sales/Revenue/Turnover	- -	1	10	14	21
+ Sales & Services Revenue	- -	1	10	14	21
- Cost of Revenue	- -	- -	- -	- -	- -
+ Cost of Goods & Services	- -	- -	- -	- -	- -
Gross Profit	- -	1	10	14	21
+ Other Operating Income	- -	- -	- -	- -	- -
- Operating Expenses	14	27	59	80	115
+ Selling, General & Admin	5	7	14	20	26
+ Research & Development	9	21	45	60	88
+ Other Operating Expense	- -	- -	- -	- -	- -
Operating Income (Loss)	-14	-26	-49	-67	-93
- Non-Operating (Income) Loss	-1	- -	- -	- -	-4
+ Interest Expense, Net	-1	- -	- -	- -	-4
+ Interest Expense	- -	- -	- -	1	4
- Interest Income	1	- -	- -	2	8
+ Other Non-Op (Income) Loss	- -	- -	- -	- -	- -
Pretax Income	-14	-26	-49	-66	-89
- Income Tax Expense (Benefit)	- -	- -	- -	- -	- -
- (Income) Loss from Affiliates	- -	- -	- -	- -	- -
Income (Loss) from Cont Ops	-14	-26	-49	-66	-89
- Net Extraordinary Losses (Gains)	- -	- -	- -	- -	- -
+ Discontinued Operations	- -	- -	- -	- -	- -
+ Extraord. & Accounting Changes	- -	- -	- -	- -	- -
Income (Loss) Incl. MI	-14	-26	-49	-66	-89
- Minority Interest	- -	- -	- -	- -	- -
Net Income, GAAP	-14	-26	-49	-66	-89
- Preferred Dividends	- -	- -	- -	- -	- -
- Other Adjustments	- -	- -	- -	- -	- -
Net Income Avail to Common, GAAP	-14	-26	-49	-66	-89
Basic Weighted Avg Shares	24	24	12	24	66
Basic EPS, GAAP	-0.57	-1.09	-4.17	-2.75	-1.36
Basic EPS from Cont Ops	-0.57	-1.09	-4.17	-2.75	-1.36
Diluted Weighted Avg Shares	24	24	12	24	66
Diluted EPS, GAAP	-0.57	-1.09	-4.17	-2.75	-1.36
Diluted EPS from Cont Ops	-0.57	-1.09	-4.17	-2.75	-1.36
EBITDA	-14	-25	-45	-61	-88
EBITDA Margin (%)	- -	-2,304.42	-446.83	-454.37	-418.53
EBITA	-14	-26	-49	-67	-93
EBIT	-14	-26	-49	-67	-93
Gross Margin (%)	- -	100	100	100	100
Operating Margin (%)	- -	-2,417.79	-479.65	-492.32	-444
Profit Margin (%)	- -	-2,408.02	-479.49	-489.26	-423.86
Sales per Employee	- -	- -	96,581	98,080	136,682
Dividend per Share	- -	- -	- -	- -	- -
Depreciation Expense	1	1	3	5	5

Balance Sheet	2019 Y	2020 Y	2021 Y	2022 Y	2023 Y
Total Current Assets	42	36	166	124	194
+ Cash, Cash Equivalents & STI	42	35	161	120	192
+ Cash & Cash Equivalents	42	35	161	120	133
+ ST Investments	- -	- -	- -	- -	59
+ Accounts & Notes Receiv	- -	- -	- -	- -	- -
+ Accounts Receivable, Net	- -	- -	- -	- -	- -
+ Notes Receivable, Net	- -	- -	- -	- -	- -
+ Loans Receivable, Net	- -	- -	- -	- -	- -
+ Other Receivable, Net	- -	- -	- -	- -	- -
+ Inventories	- -	- -	- -	- -	- -
+ Raw Materials	- -	- -	- -	- -	- -
+ Work In Process	- -	- -	- -	- -	- -
+ Finished Goods	- -	- -	- -	- -	- -
+ Inventory Adjustments	- -	- -	- -	- -	- -
+ Other Inventory	- -	- -	- -	- -	- -
+ Other ST Assets	1	2	4	4	2
+ Prepaid Expenses	- -	- -	- -	- -	- -
+ ST Derivative & Hedging Assets	- -	- -	- -	- -	- -
+ ST Assets Held-for-Sale	- -	- -	- -	- -	- -
+ ST Deferred Tax Assets	- -	- -	- -	- -	- -
+ Misc ST Assets	- -	- -	- -	- -	- -
Total Noncurrent Assets	7	13	22	75	78
+ Property, Plant & Equip, Net	6	13	17	69	71
+ Property, Plant & Equip	7	14	22	79	86
- Accumulated Depreciation	1	2	5	10	15
+ LT Investments & Receivables	- -	- -	- -	- -	- -
+ LT Investments	- -	- -	- -	- -	- -
+ LT Receivables	- -	- -	- -	- -	- -
+ Other LT Assets	1	1	5	6	7
+ Total Intangible Assets	- -	- -	- -	- -	- -
+ Goodwill	- -	- -	- -	- -	- -
+ Other Intangible Assets	- -	- -	- -	- -	- -
+ LT Deferred Tax Assets	- -	- -	- -	- -	- -
+ LT Derivative & Hedging Assets	- -	- -	- -	- -	- -
+ Misc LT Assets	1	1	5	6	7
Total Assets	49	50	188	199	272
+ Payables & Accruals	1	4	5	5	7
+ Accounts Payable	1	3	2	3	2
+ Accrued Taxes	- -	- -	- -	- -	- -
+ Interest & Dividends Payable	- -	- -	- -	- -	- -
+ Other Payables & Accruals	- -	1	3	2	5
+ ST Debt	- -	1	2	4	7
+ ST Borrowings	- -	- -	- -	- -	3
+ ST Finance Leases	- -	1	2	4	3
+ Other ST Liabilities	1	12	15	9	16
+ Deferred Revenue	- -	11	11	4	10
+ Derivatives & Hedging	- -	- -	- -	- -	- -
+ Deferred Tax Liabilities	- -	- -	- -	- -	- -
+ Misc ST Liabilities	1	2	4	5	6
Total Current Liabilities	2	17	21	17	30
+ LT Debt	4	6	4	82	86
+ LT Borrowings	- -	- -	- -	29	27
+ LT Finance Leases	4	6	4	53	59
+ Other LT Liabilities	60	69	2	- -	6
+ Accrued Liabilities	- -	9	1	- -	6
+ Pension Liabilities	- -	- -	- -	- -	- -
+ Deferred Revenue	- -	- -	- -	- -	- -
+ Deferred Tax Liabilities	- -	- -	- -	- -	- -
+ Derivatives & Hedging	- -	- -	- -	- -	- -
+ Misc LT Liabilities	60	60	- -	- -	- -
Total Noncurrent Liabilities	64	75	6	82	91
Total Liabilities	67	92	27	100	121
+ Preferred Equity and Hybrid Capital	- -	- -	- -	- -	- -
+ Share Capital & APIC	- -	1	253	258	398
+ Common Stock	- -	- -	- -	- -	- -
+ Additional Paid in Capital	- -	1	253	258	398
- Treasury Stock	- -	- -	- -	- -	- -
+ Retained Earnings	-17	-44	-92	-158	-248
+ Other Equity	- -	- -	- -	- -	- -
Equity Before Minority Interest	-17	-42	161	99	151
+ Minority/Non Controlling Interest	- -	- -	- -	- -	- -
Total Equity	-17	-42	161	99	151
Total Liabilities & Equity	49	50	188	199	272
Shares Outstanding	24	24	24	24	48
Capital Leases - Total	5	7	6	57	62
Net Debt	-42	-35	-161	-91	-103
Net Debt to Equity	243.69	81.93	-100.39	-91.25	-68.48
Tangible Common Equity Ratio	-34.7	-85.37	85.47	49.94	55.44
Current Ratio	17.69	2.09	7.76	7.17	6.51
Cash Conversion Cycle	- -	- -	- -	- -	- -
Number of Employees	- -	- -	105	138	154

Cash Flow Statement	2019 Y	2020 Y	2021 Y	2022 Y	2023 Y
+ Net Income	-14	-26	-49	-66	-89
+ Depreciation & Amortization	1	1	3	5	5
+ Non-Cash Items	- -	1	3	5	5
+ Stock-Based Compensation	- -	1	3	5	5
+ Deferred Income Taxes	- -	- -	- -	- -	- -
+ Asset Impairment Charge	- -	- -	- -	- -	- -
+ Other Non-Cash Adj	- -	- -	- -	- -	- -
+ Chg in Non-Cash Work Cap	- -	21	-6	-10	18
+ (Inc) Dec in Accts Receiv	- -	- -	- -	- -	- -
+ (Inc) Dec in Inventories	- -	- -	- -	- -	- -
+ (Inc) Dec in Prepaid Assets	- -	-1	-3	- -	1
+ Inc (Dec) in Accts Payable	1	3	3	1	4
+ Inc (Dec) in Other	- -	20	-7	-11	13
+ Net Cash From Disc Ops	- -	- -	- -	- -	- -
Cash from Operating Activities	-13	-3	-49	-67	-61
+ Change in Fixed & Intang	- -	- -	- -	- -	- -
+ Disp in Fixed & Intang	- -	- -	- -	- -	- -
+ Disp of Fixed Prod Assets	- -	- -	- -	- -	- -
+ Disp of Intangible Assets	- -	- -	- -	- -	- -
+ Acq of Fixed & Intang	-1	-4	-10	-4	-3
+ Acq of Fixed Prod Assets	-1	-4	-10	-4	-3
+ Acq of Intangible Assets	- -	- -	- -	- -	- -
+ Net Change in LT Investment	- -	- -	- -	- -	-58
+ Dec in LT Investment	- -	- -	- -	- -	20
+ Inc in LT Investment	- -	- -	- -	- -	-78
+ Net Cash From Acq & Div	- -	- -	- -	- -	- -
+ Cash from Divestitures	- -	- -	- -	- -	- -
+ Cash for Acq of Subs	- -	- -	- -	- -	- -
+ Cash for JVs	- -	- -	- -	- -	- -
+ Other Investing Activities	- -	- -	- -	- -	- -
+ Net Cash From Disc Ops	- -	- -	- -	- -	- -
Cash from Investing Activities	-1	-4	-10	-4	-61
+ Dividends Paid	- -	- -	- -	- -	- -
+ Net Cash From Debt	- -	- -	- -	29	- -
+ Cash From Debt	- -	- -	- -	29	- -
+ Repayments of Debt	- -	- -	- -	- -	- -
+ Cash (Repurchase) of Equity	- -	- -	90	- -	42
+ Increase in Capital Stock	- -	- -	90	- -	42
+ Decrease in Capital Stock	- -	- -	- -	- -	- -
+ Other Financing Activities	35	- -	100	- -	93
+ Net Cash From Disc Ops	- -	- -	- -	- -	- -
Cash from Financing Activities	35	- -	190	29	135
Effect of Foreign Exchange Rates	- -	- -	- -	- -	- -
Net Changes in Cash	21	-7	131	-41	13
EBITDA	-14	-25	-45	-61	-88
EBITDA Margin (%)	- -	-2,304.42	-446.83	-454.37	-418.53
Net Cash Paid for Acquisitions	- -	- -	- -	- -	- -
Free Cash Flow	-14	-7	-59	-71	-65
Free Cash Flow to Firm	- -	- -	- -	- -	- -
Free Cash Flow to Equity	- -	-7	-59	-41	-65
Free Cash Flow per Basic Share	-0.58	-0.3	-5.03	-2.94	-0.98
Price/Free Cash Flow	- -	- -	-1.43	-0.67	-6.72
Cash Flow to Net Income	0.92	0.12	1	1	0.69

TScan Therapeutics, Inc.

TCRX US

9.00